Aon plc's Managed Care Services Team has completed a review of DarioHealth Corp.'s AI-powered chronic condition management services, concluding that the evidence supports estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population. For a representative population of 20,000 covered lives, that translates to approximately $3.8 million to $10.8 million in annual savings, according to the review. The findings, announced by DarioHealth (NASDAQ: DRIO), carry significant implications for health plans, health systems and employers seeking to control rising chronic care costs.
The Aon review evaluated 17 studies spanning cardiometabolic, musculoskeletal and behavioral health conditions, including both independently conducted and company-sponsored research. Aon found consistent reported improvements across clinical, behavioral, healthcare utilization and cost measures, and concluded that the evidence supports an association between DarioHealth services and meaningful clinical and financial outcomes. Importantly, Aon also estimated that management of multiple conditions and access to physicians—factors excluded from the initial calculations—could contribute an additional 1.6 to 2.8 percentage points in savings. That upside suggests the total financial impact may be even greater than the headline range indicates.
For payers and employers, the review provides third-party validation of DarioHealth's integrated platform, which combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care. The company's AI platform leverages more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade to personalize care at the individual member level, analyzing biometric, clinical and behavioral data to deliver timely interventions. By addressing diabetes, hypertension, weight management, musculoskeletal and behavioral health needs within a single solution, DarioHealth aims to help customers manage multiple chronic conditions more efficiently. The full press release is available at https://ibn.fm/IFvLH.
However, the review has limitations. Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. Despite these caveats, the conclusions may bolster DarioHealth's position in a competitive digital health market where proven cost savings are a key differentiator. The latest news and updates relating to DRIO are available in the company's newsroom at https://ibn.fm/DRIO.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio within IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and other services. The review's findings may influence how employers and health plans evaluate chronic condition management vendors, particularly as they seek measurable returns on healthcare investments.
